Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Acquired by Mariner LLC

Mariner LLC lifted its position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 14.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 142,504 shares of the company's stock after acquiring an additional 17,525 shares during the quarter. Mariner LLC's holdings in Takeda Pharmaceutical were worth $1,887,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Versant Capital Management Inc bought a new position in shares of Takeda Pharmaceutical during the 4th quarter valued at $26,000. Wilmington Savings Fund Society FSB purchased a new stake in Takeda Pharmaceutical in the third quarter worth about $40,000. Farther Finance Advisors LLC lifted its stake in shares of Takeda Pharmaceutical by 123.6% in the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after buying an additional 1,976 shares in the last quarter. Crowley Wealth Management Inc. bought a new position in Takeda Pharmaceutical during the fourth quarter valued at approximately $52,000. Finally, Cromwell Holdings LLC bought a new position in Takeda Pharmaceutical during the fourth quarter valued at approximately $61,000. Institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Price Performance

Takeda Pharmaceutical stock remained flat at $15.28 during trading hours on Wednesday. 1,807,826 shares of the company's stock were exchanged, compared to its average volume of 1,869,650. The company has a market capitalization of $48.62 billion, a P/E ratio of 38.20, a price-to-earnings-growth ratio of 0.24 and a beta of 0.39. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The stock has a 50 day moving average of $14.81 and a 200 day moving average of $13.96. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.58 and a fifty-two week high of $15.37.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, sell-side analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.